NCT02582632View on ClinicalTrials.gov

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

166

Participants

Timeline

Start Date

November 24, 2015

Primary Completion Date

August 24, 2016

Study Completion Date

December 1, 2016

Conditions

Hepatitis C InfectionHepatitis C Virus

Interventions

DRUG

ombitasvir/paritaprevir/ritonavir

Tablet

DRUG

dasabuvir

Tablet

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AbbVie

INDUSTRY